CN108291248A - 对atp结合位点进行突变的血管内皮抑制素突变体 - Google Patents

对atp结合位点进行突变的血管内皮抑制素突变体 Download PDF

Info

Publication number
CN108291248A
CN108291248A CN201280078261.4A CN201280078261A CN108291248A CN 108291248 A CN108291248 A CN 108291248A CN 201280078261 A CN201280078261 A CN 201280078261A CN 108291248 A CN108291248 A CN 108291248A
Authority
CN
China
Prior art keywords
mutant
seq
endostatin
amino acid
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201280078261.4A
Other languages
English (en)
Other versions
CN108291248B (zh
Inventor
罗永章
刘鹏
鲁薪安
陈阳
付彦
常国栋
周代福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Priority to CN202410186085.0A priority Critical patent/CN117987505A/zh
Publication of CN108291248A publication Critical patent/CN108291248A/zh
Application granted granted Critical
Publication of CN108291248B publication Critical patent/CN108291248B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明涉及新的抗肿瘤药物。具体而言，本发明提供血管内皮抑制素的突变体，所述突变体具有降低的ATPase活性和提高的新生血管生成抑制活性。本发明还提供所述突变体在治疗肿瘤等新生血管相关疾病中的用途。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201280078261.4A 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体 Active CN108291248B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410186085.0A CN117987505A (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201110280441.8 2011-09-09
CN2011102804418 2011-09-09
CN201110280441 2011-09-09
PCT/CN2012/081210 WO2013034116A1 (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410186085.0A Division CN117987505A (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Publications (2)

Publication Number Publication Date
CN108291248A true CN108291248A (zh) 2018-07-17
CN108291248B CN108291248B (zh) 2024-03-08

Family

ID=47831548

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280078261.4A Active CN108291248B (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体
CN202410186085.0A Pending CN117987505A (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410186085.0A Pending CN117987505A (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Country Status (10)

Country Link
US (1) US10647968B2 (zh)
EP (1) EP2754718B1 (zh)
JP (1) JP6336389B2 (zh)
CN (2) CN108291248B (zh)
AU (1) AU2012306826B2 (zh)
CA (1) CA2848118C (zh)
HK (1) HK1251864A1 (zh)
IL (1) IL231419A0 (zh)
RU (1) RU2014113924A (zh)
WO (1) WO2013034116A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
WO2016070798A1 (zh) * 2014-11-03 2016-05-12 清华大学 一种抑制脂肪细胞分化和胰岛素耐受的药物
AU2016218635B2 (en) * 2015-02-13 2020-07-23 Beijing Protgen Ltd. Molecular design of recombinant protein drug
CN110452295B (zh) * 2015-11-10 2022-10-11 孙嘉琳 抗肿瘤蛋白内皮抑素的衍生物
CA3043380A1 (en) * 2016-11-10 2018-05-17 Beijing Protgen Ltd. Pegylated endostatin analogue and application thereof
CA3103035A1 (en) * 2017-07-30 2019-02-07 Tsinghua University Medication for inhibiting dna-pkcs
CN114645025B (zh) * 2022-04-13 2023-12-22 南开大学 一种人源atp合成酶的纯化方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324818A (zh) * 2000-05-22 2001-12-05 烟台荣昌生物工程有限公司 生产内皮抑制素的方法
US7339027B2 (en) * 2002-05-31 2008-03-04 Ghc Research Development Corporation Human prolactin antagonist-angiogenesis inhibitor fusion proteins
CN101256139A (zh) * 2008-04-18 2008-09-03 山东先声麦得津生物制药有限公司 一种血管内皮抑制素生物活性的检测方法
CN101890155A (zh) * 2010-05-25 2010-11-24 江苏先声药物研究有限公司 一种药物组合物及其应用
US20110092441A1 (en) * 2008-04-04 2011-04-21 Procell Therapeutics Inc Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312287A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins: endostatin, angiostatin or restin, using a pichia yeast expression system
WO2000067771A1 (en) * 1999-05-06 2000-11-16 The Burnham Institute Antiangiogenic endostatin peptides, endostatin variants and methods of use
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324818A (zh) * 2000-05-22 2001-12-05 烟台荣昌生物工程有限公司 生产内皮抑制素的方法
US7339027B2 (en) * 2002-05-31 2008-03-04 Ghc Research Development Corporation Human prolactin antagonist-angiogenesis inhibitor fusion proteins
US20110092441A1 (en) * 2008-04-04 2011-04-21 Procell Therapeutics Inc Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component
CN101256139A (zh) * 2008-04-18 2008-09-03 山东先声麦得津生物制药有限公司 一种血管内皮抑制素生物活性的检测方法
CN101890155A (zh) * 2010-05-25 2010-11-24 江苏先声药物研究有限公司 一种药物组合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
袁绍鹏: "人血管内皮抑素诱导内皮细胞凋亡的机理研究", 《中国博士学位论文全文数据库（电子期刊）》 *

Also Published As

Publication number Publication date
CA2848118A1 (en) 2013-03-14
US20150197733A9 (en) 2015-07-16
JP6336389B2 (ja) 2018-06-06
IL231419A0 (en) 2014-04-30
CA2848118C (en) 2023-09-05
CN117987505A (zh) 2024-05-07
US20140308263A1 (en) 2014-10-16
EP2754718A1 (en) 2014-07-16
EP2754718B1 (en) 2017-12-13
AU2012306826A1 (en) 2014-04-03
WO2013034116A1 (zh) 2013-03-14
RU2014113924A (ru) 2015-10-20
HK1251864A1 (zh) 2019-04-26
CN108291248B (zh) 2024-03-08
EP2754718A4 (en) 2015-04-22
JP2014531897A (ja) 2014-12-04
AU2012306826B2 (en) 2018-01-04
US10647968B2 (en) 2020-05-12

Similar Documents

Publication Publication Date Title
CN108291248A (zh) 对atp结合位点进行突变的血管内皮抑制素突变体
Bova et al. Subunit exchange of small heat shock proteins: analysis of oligomer formation of αA-crystallin and Hsp27 by fluorescence resonance energy transfer and site-directed truncations
KR101867359B1 (ko) 엔도리보뉴클레아제 조성물들 및 이들의 사용 방법들
US11965003B2 (en) Recombinant lectin variants
CN1886500A (zh) 磷酸激酶及其应用
CN107501405B (zh) 一种细胞自噬抑制多肽
WO2009095452A1 (en) Crystal structure of the atpase domain of proteins of the hsp70 family
US20210309984A1 (en) ChiA Enzyme
Sarkhosh-Inanlou et al. The response of PIK3CA/KRAS-mutant colorectal cancer stem-like cells to RGD-peptide FraC produced by the strawberry anemone: A promising water-soluble peptide-based inhibitor of metastasis-driver gene CXCR4, stem cell regulatory genes and self-renewal
Nesiel-Nuttman et al. Human RNASET2 derivatives as potential anti-angiogenic agents: actin binding sequence identification and characterization
JP2013502217A (ja) ａｒＮＯＸタンパク質９回膜貫通型スーパーファミリー（ＴＭ９ＳＦ）のクローニング及び発現、方法並びに利用
JP2016141678A (ja) ヒトｈｍｇｂ１結合剤、ヒトｈｍｇｂ１除去装置および新規ポリペプチド
WO2008029807A1 (fr) Nouveau polypeptide ayant une cytotoxicité contre le cancer, procédé pour cribler le polypeptide et utilisation du polypeptide
KR101841646B1 (ko) 암 억제 표적 단백질인 ａｉｍｐ－ｄｘ2의 제조방법
RU2458987C1 (ru) Способ получения рекомбинантного фрагмента плазминогена человека, обладающего антиангиогенным действием
US20240141299A1 (en) Cofactors FAD and PLP for Promoting Pancreatic Progenitors in Pancreatic Development
BR102016020994A2 (pt) Processo de obtenção da proteína l-lisina alfa- oxidase recombinante (rlo), iniciadores, proteína rlo obtida e seu uso
Kim et al. Functional analysis of duplicated genes and N-terminal splice variant of phospholipase C-δ1 in Paralichthys olivaceus
Al Ameer Cloning, Protein Expression, and Characterization of Interleukin 1 Alpha
Schafer Extending the HECT Domain of HERC4 Improves Solubility and Catalysis
RU2565545C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pFLAG-sc14D5a-Rm7, ОБЕСПЕЧИВАЮЩАЯ СИНТЕЗ ГИБРИДНОГО БЕЛКА sc14D5a-Rm7, ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО БЕЛКА sc14D5a-Rm7 И ГИБРИДНЫЙ БЕЛОК sc14D5a-Rm7, СВЯЗЫВАЮЩИЙ БЕЛОК Е ВИРУСА КЛЕЩЕВОГО ЭНЦЕФАЛИТА И ОБЛАДАЮЩИЙ БИОЛЮМИНЕСЦЕНТНОЙ АКТИВНОСТЬЮ
WO2015174641A1 (ko) Aimp2-dx2-34s 단백질 및 이의 제조방법
KR20230051899A (ko) Usp44-wdr5 복합체 결정 및 결정화 방법
CN110946853A (zh) 莪术醇在制备nqo2蛋白抑制剂中的应用
CN102735843A (zh) Jmjd8基因及表达产物对肝癌细胞生长的抑制作用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1251864

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant